TNXP Tonix Pharmaceuticals Holding Corp.

1.52
-0.12  -7%
Previous Close 1.64
Open 1.67
Price To Book 1.31
Market Cap 12,965,986
Shares 8,530,254
Volume 904,396
Short Ratio
Av. Daily Volume 2,323,290
Stock charts supplied by TradingView

NewsSee all news

  1. Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL

     Tonix Expects the Data to Satisfy Pharmacokinetic Requirements for Potential New Drug Applications for TNX-102 SL for PTSD and Fibromyalgia Lack of a Food Effect for TNX-102 SL Supports Predictability of Therapeutic

  2. Tonix Pharmaceuticals to Present at Biotech Showcase 2020

    NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will

  3. Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study

    TNX-601 CR Active Ingredient, Tianeptine, is Approved and Marketed as an Immediate Release Three-Times-a-Day Antidepressant in Europe, Asia, Russia and Latin America First Efficacy Trial Planned ex-U.S. in 2020 NEW

  4. Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL

    NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European Patent Office

  5. Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

    Interim Analysis Results Expected Second Half 2020 Topline Results Expected First Half 2021 Based on the Currently-Planned Sample Size NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial halted due to insufficient efficacy - July 27, 2018.
TNX-102 SL (Tonmya)
Post-traumatic stress disorder (PTSD)
Phase 2 data released February 2016 did not meet primary endpoint
TNX-201
Episodic tension-type headache
Phase 3 commencement of enrolment announced December 10, 2019. Interim analysis due 2H 2020. Top-line data due 1H 2021.
TNX-102 SL
Fibromyalgia
Phase 3 interim analysis 1Q 2020 with top-line data due 2Q 2020.
Tonmya
Post-traumatic stress disorder (PTSD)
In-licensed - noted May 23, 2019.
TNX-1300 (RBP-8000)
Cocaine intoxication
Efficacy trial to commence in 2020.
TNX-601
PK trial

Latest News

  1. Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL

     Tonix Expects the Data to Satisfy Pharmacokinetic Requirements for Potential New Drug Applications for TNX-102 SL for PTSD and Fibromyalgia Lack of a Food Effect for TNX-102 SL Supports Predictability of Therapeutic

  2. Tonix Pharmaceuticals to Present at Biotech Showcase 2020

    NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will

  3. Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study

    TNX-601 CR Active Ingredient, Tianeptine, is Approved and Marketed as an Immediate Release Three-Times-a-Day Antidepressant in Europe, Asia, Russia and Latin America First Efficacy Trial Planned ex-U.S. in 2020 NEW

  4. Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL

    NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European Patent Office

  5. Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

    Interim Analysis Results Expected Second Half 2020 Topline Results Expected First Half 2021 Based on the Currently-Planned Sample Size NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp.

  6. Tonix Pharmaceuticals to Present at 12th Annual LD Micro Main Event

    NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) announced today that Company management will present at the 12th Annual LD Micro Main Event being

  7. Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

    NEW YORK, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, today announced that it has regained compliance with the

  8. Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD

    Minutes are Consistent with Guidance Received at FDA Meeting More Than 50 Percent of Enrollment Completed for Phase 3 RECOVERY Trial of Tonmya for PTSD Results from RECOVERY Interim Analysis Expected First Quarter 2020

  9. Tonix Pharmaceuticals to Participate in Benchmark's Annual Discovery 1x1 Conference

    NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be

  10. Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

    NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that, having successfully closed an

  11. Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder

    NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has received the official meeting

  12. Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering

    NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), clinical-stage biopharmaceutical company, announced today the closing of its previously announced

  13. Tonix Pharmaceuticals Prices $9.0 Million Public Offering

    NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public

  14. Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

    50% of Enrollment Complete for Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD Results from RECOVERY Interim Analysis Expected First Quarter 2020 Topline Data Expected Second Quarter 2020 Based on

  15. Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting

    Primary Endpoint Will be Mean Change from Baseline in CAPS-5 at Week 12, Instead of Week 4 Results from Added Interim Analysis Expected in First Quarter 2020 Topline Data Expected in Second Quarter 2020 Based on

  16. Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

    NEW YORK, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect a 1-for-10 reverse

  17. Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601

    NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark

  18. Tonix Pharmaceuticals Joins the Alliance for Biosecurity

    NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has joined the Alliance for

  19. Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD

    NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European Patent Office's (EPO)

  20. Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg

    NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced Tonix has completed collecting the

  21. Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers

    NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has obtained an exclusive

  22. Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology

    NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of a paper entitled

  23. Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans' Research and Education Foundations (NAVREF) Conference

    NEW YORK, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will

  24. Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) announced today that Company management will present at three upcoming investor conferences.

  25. Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that participants were dosed in a Phase